Charles Hu, Ph.D.

A translational biomedical engineer with a strong background in business development and investments, Charles’s vision is in bringing about a vibrant healthcare innovation and investment ecosystem in the HK Greater Bay Area. He obtained his PhD from Johns Hopkins University, BS from University of California, Berkeley, and his scientific expertise interfaces across biomedical engineering, regenerative medicine, interventional radiology, and materials science. He is also experienced in research commercialization and in MNC pharma product development and medical affairs. He co-founded Incando Therapeutics to bring innovative therapeutic technologies to the clinical stage and targeting difficult to treat diseases including recurrent cancer and neurodegenerative diseases. On the business front, Charles heads Ryoden Medical Holdings where he oversees healthcare venture investments for his family office, advises angel investors and startups, and actively engages in policy discussions in support of biomedical innovations and youth talent development.

Charles is a visiting Assistant Professor of Biomedical Sciences and Industrial Advisor of Biomedical Engineering at the City University of Hong Kong, vice president of the BIOHK international biotechnology conventions, board member of two biotechnology companies, member of the Hong Kong Professionals and Senior Executives Association (HKPASEA) and the Hong Kong Biotechnology Organization (HKBIO), and director of several retail, food & beverage, and real estate businesses. He was awarded the Outstanding Young Entrepreneur Award and Best Sci-Tech Innovation Project in 2023 by the Guangdong-HK-Macao Bay Area Entrepreneurs Union and the Chinese General Chamber of Commerce (“CGCC”) in Hong Kong.